Overview

• Pfizer agreed to offer Medicaid the lowest prices it charges in peer countries and to launch new drugs in the U.S. at parity with those markets.
• The White House says TrumpRx will act as a government convening site that directs users to manufacturers’ direct‑to‑consumer portals, with availability targeted for early 2026.
• Pfizer said it will provide average discounts of about 50% through the direct‑to‑consumer channel, with some medicines discounted as much as 85%, though detailed terms remain confidential.
• In exchange, the administration granted Pfizer a three‑year exemption from threatened 100% tariffs and the company pledged $70 billion for U.S. manufacturing and research.
• Officials and independent analysts say price changes are expected in 2026 and may primarily reduce state Medicaid spending, as the deal does not extend to Medicare or private insurance while talks with other drugmakers continue.